Blog
RSS FeedPosted by Michael Wonder on 18 Jun 2025
Obecabtagene autoleucel for the treatment of patients with relapsed or refractory B-cell acute lymphoblastic leukaemia
13 June 2025 - The Department of Health and Social Care has asked NICE to produce guidance on the use ...
Posted by Michael Wonder on 18 Jun 2025
PHARMAC declines inactive medicine applications
18 June 2025 - PHARMAC has declined 48 inactive funding applications so that it is clearer what medicines are currently ...
Posted by Michael Wonder on 16 Jun 2025
New Chief Executive for PHARMAC
17 June 2025 - PHARMAC’s Board has appointed a new Chief Executive to lead the organisation. ...
Posted by Michael Wonder on 16 Jun 2025
EMA publishes agenda for 16-19 June 2025 CHMP meeting
16 June 2025 - The EMA has published a draft agenda for this week's CHMP meeting. ...
Posted by Michael Wonder on 14 Jun 2025
NICE leads the way in approving breakthrough treatment for multiple myeloma
13 June 2025 - People in England will become the first in the world to receive belantamab mafodotin for this indication ...
Posted by Michael Wonder on 13 Jun 2025
AbbVie’s Epkinly, Eisai’s Lenvima pass reimbursement review; Janssen’s Tecvayli fails
11 June 2025 - AbbVie Korea's Epkinly (epcoritamab), a treatment for adults with relapsed or refractory diffuse large B-cell lymphoma ...
Posted by Michael Wonder on 10 Jun 2025
DoH publishes revised agenda for July 2025 PBAC meeting (version 4)
10 June 2025 - The DoH has published a revised agenda for next month's PBAC meeting. ...
Posted by Michael Wonder on 09 Jun 2025
SMC - June 2025 decisions
9 June 2025 - The SMC, which advises on newly licensed medicines for use by NHSScotland, has today published advice ...
Posted by Michael Wonder on 06 Jun 2025
Biogen disappointed by INESSS recommendation on Skyclarys and its impact on Quebec patients with Friedreich ataxia
5 June 2025 - Biogen Canada is disappointed by INESSS's recommendation against listing Skyclarys (omaveloxolone), despite its therapeutic potential for ...
Posted by Michael Wonder on 04 Jun 2025
DoH publishes revised agenda for May 2025 PBAC meeting in June!
4 June 2025 - The DoH has published a revised agenda for last month's PBAC meeting. ...
Posted by Michael Wonder on 02 Jun 2025
RSV prophylaxis with nirsevimab: benefits for healthy children in the first RSV season
2 June 2025 - Children immunised with the antibody nirsevimab are significantly less likely to develop RSV-related lower respiratory tract infections. ...
Posted by Michael Wonder on 02 Jun 2025
Garadacimab in hereditary angioedema: evidence of considerable additional benefit
2 June 2025 - An indirect comparison shows a significant reduction in the monthly rate of attacks and other benefits. ...
Posted by Michael Wonder on 29 May 2025
ICER publishes evidence report on treatment for secondary progressive multiple sclerosis
29 May 2025 - There are significant uncertainties regarding long term efficacy of tolebrutinib; ICER estimates that treatment would achieve ...
Posted by Michael Wonder on 27 May 2025
ICER releases draft evidence report on treatments for spinal muscular atrophy
27 May 2025 - Public comment period now open until 24 June 2025; requests to make oral comment during public ...
Posted by Michael Wonder on 25 May 2025
CHMP recommends EU approval of Roche’s Itovebi for PIK3CA mutated, ER positive, HER2 negative, advanced breast cancer
23 May 2025 - Positive recommendation based on Phase 3 INAVO120 data showing Itovebi (inavolisib) in combination with palbociclib and fulvestrant ...